Emerging therapeutics for the management of intestinal fibrosis and strictures

Yub Raj Neupane, Thanuja Marasarakottige Yogananda, Sri Vishnu Kiran Rompicharla, Florin M. Selaru, Laura M. Ensign

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Chronic intestinal inflammation in patients with inflammatory bowel disease (IBD) can lead to the development of fibrosis and the formation of strictures. Endoscopic balloon dilation and surgical resection are currently the only available treatments for fibrotic strictures. However, both strategies are associated with potential complications and high rates of stricture recurrence, necessitating additional procedures and/or multiple surgical resections. IBD therapeutic modalities aimed at inflammation, including anti-inflammatory agents, such as corticosteroids, biologics and small molecules, have shown limited efficacy in altering the natural history of strictures, ameliorating fibrosis progression, or preventing recurrences. New and innovative therapeutic approaches targeted at fibrosis are urgently needed. Herein, we provide an overview of emerging therapeutics, including novel drug delivery systems, for the management of intestinal fibrosis and strictures.

Original languageEnglish (US)
Title of host publicationEmerging Therapeutic Targets and Drug Delivery Approaches in IBD
EditorsFlorin M. Selaru, Diane E. Peters
PublisherAcademic Press Inc.
Pages107-139
Number of pages33
ISBN (Print)9780443313585
DOIs
StatePublished - Jan 2024

Publication series

NameAdvances in Pharmacology
Volume101
ISSN (Print)1054-3589
ISSN (Electronic)1557-8925

Keywords

  • Crohn's disease
  • IBD
  • Intestinal fibrosis
  • Novel drug delivery
  • Strictures

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Emerging therapeutics for the management of intestinal fibrosis and strictures'. Together they form a unique fingerprint.

Cite this